Intangible Assets, Net

12 Months Ended

Jun. 30, 2025

Intangible Assets, Net [Abstract]

INTANGIBLE ASSETS, NET

NOTE 7 — INTANGIBLE ASSETS, NET

Net intangible assets consists of the following:

	June 30, 2025			June 30, 2024
License	$	418,867		$	-
Less: accumulated amortization		(53,427	)		-
Intangible asset, net	$	365,440		$	-

On November 5, 2024, the Company purchased a license of pharmaceutical distribution in Mainland China through its acquisition of 100% equity interest in Hupan Pharmaceutical. The Company recognized the distribution license as an intangible asset of $418,867 based on the assessment of fair value at the purchase date (see Note 21), adjusted by deferred taxes impact on temporary tax differences in an asset acquisition using the simultaneous equations method. The transaction was closed on November 21, 2024. No impairment expense was recognized for the year ended June 30, 2025. Amortization expense of $53,427 was recognized for the year ended June 30, 2025.